We are pleased to announce that Exogenus Therapeutics has been granted another patent, now in Europe! This is the fifth region to recognize the patent family titled “Use of umbilical cord blood-derived exosomes for tissue repair.” This patent family has also been granted in Canada, China, Japan and Korea. This invention leverages exosomes naturally released by umbilical cord blood cells, subjected to a specific pre-conditioning environment, and provides a therapeutic approach for regenerative medicine. Exogenus has thoroughly characterized these exosomes and their bioactivity, uncovering a multifactorial mechanism of action. Our CEO, Joana Correia, also inventor of the patent, stated: “This new European patent is a significant achievement for Exogenus Therapeutics. It opens doors to a robust international market, strengthens our patent portfolio, and highlights our commitment to innovation.” Exogenus Therapeutics' patent portfolio includes three families related to its lead product, Exo-101, covering different aspects of its composition, manufacturing process, and therapeutic applications (including inflammatory and fibrotic diseases). As a leading exosome biotech company, Exogenus is dedicated to developing innovative, safe, and effective therapies for patients with significant unmet needs. The company now plans to broaden the applications of its proprietary exosomes to treat a diverse range of conditions involving tissue...

Exogenus Therapeutics Chooses Lonza to Develop a GMP-Compliant Process to Manufacture Exo-101, its Lead Exosome-Based Candidate Lonza to develop a GMP-compliant process for Exo-101 manufacturing from its Siena (IT) site Exo-101 has shown safety and efficacy in multiple pre-clinical trials, and is expected to reach patients in 2027 Basel, Switzerland and Cantanhede, Portugal, 11 March 2025 – Exogenus Therapeutics, a Portuguese biotech company, and Lonza, a global development and manufacturing partner to the pharmaceutical and biotech markets, announced today a collaboration to develop Exo-101, Exogenus’ exosome-based lead candidate.Exogenus Therapeutics specializes in the development of healthcare solutions based on extracellular vesicles, including exosomes and other nanotechnologies. The company’s lead product, Exo-101, derived from immunologically privileged cells from umbilical cord blood, has been shown to have regenerative, anti‑inflammatory and immunomodulatory properties in multiple preclinical models and is expected to reach patients in 2027. Its multifactorial mode-of-action, mediated by a cocktail of small RNAs, proteins and anti-inflammatory lipids, provides the foundation for the drug’s therapeutic potential and positive safety profile[1],[2]. Exo-101 targets patients lacking effective treatment options primarily in the areas of tissue regeneration and inflammatory diseases.Under the agreement, Lonza will leverage its expertise in exosome development and analytical services from its Siena...

We are pleased to announce that ExogenusTherapeutics has been granted another patent in Japan! This is the second patent granted in this region, and the first one to be granted within the family entitled "Compositions comprising small extracellular vesicles derived from umbilical cord blood mononuclear cells with anti-inflammatory and immunomodulatory properties and process for obtaining them".  This invention covers the use of exosomes that are naturally secreted by umbilical cord blood mononuclear cells subjected to a specific pre-conditioning, as a therapeutic option for diseases associated to inflammation and immune deregulation. Exogenus Therapeutics has deeply characterized these exosomes and their bioactivity, and demonstrated a multifactorial mechanism-of-action that is largely associated to specific microRNAs.   Our CEO, Joana Correia, and co-inventor of the patent remarked, “This new patent granted in Japan is a milestone for Exogenus Therapeutics, as it allows us to explore a strong international market, strengthens our patent portfolio, and demonstrates our focus in innovation.”  As a leading exosome biotech company, Exogenus Therapeutics is committed to developing innovative, effective, and safe therapies for patients with high unmet medical needs. The company now aims to expand the use of its proprietary exosomes as a treatment for different therapeutic applications that involve...